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Abstract
Excessive bleeding complicates surgery and may result in a higher risk of 
morbidity in dentistry. Although multiple evidence-based clinical guidelines regard 
dental interventions as minor procedures, with low risk of bleeding, patients on 
anticoagulation therapy are at elevated risk of bleeding complications, during 
and following dental surgeries. In many instances, discontinuation or altering of 
anticoagulation can be avoided through the use of local hemostatic agents during or 
after the procedure (or both), while patients are therapeutically continued on their 
prescribed anticoagulant doses. In addition, patients with diagnosis of hereditary 
bleeding disorders, such as von Willebrand disease and hemophilia, and individu-
als without any history of bleeding complications can present the need for the use 
of topical hemostatic agents. In this chapter, we discuss the mechanisms of action, 
practical applications, effectiveness, and potential negative effects of biosurgical 
topical hemostatic agents, such as gelatin sponges, collagen, oxidized regenerated 
cellulose (ORC) and oxidized cellulose, fibrin sealants, flowables, adhesives, and 
topical thrombin in dental surgery.
Keywords: bleeding, antiplatelet, hemostasis, biosurgical agents, topical agents, 
dental surgery
1. Introduction
All surgical procedures, including dental surgery, present risk of complica-
tions, which may include pain, nerve injury, swelling, infections, and hemorrhage. 
Dental surgery is defined as any dental intervention including an incision in the oral 
mucosa or gingiva, including anything from a simple dental extraction to alveolo-
plasties [1]. Bleeding control is an important step during dental surgery procedures 
[2] because excessive bleeding complicates surgery and increases the risk of 
morbidity. To avoid such complications when long-lasting bleeding occurs, despite 
the proper use of traditional techniques for hemorrhage control, a broad range of 
hemostatic agents are available, as adjunctive measures to enhance hemostasis in the 
course of dental surgeries [3]. Despite the expressive rise in the amount and types 
of topical hemostats in the past decade, high-level evidence regarding the manage-
ment of these agents during bleeding in dental surgery is still lacking.
The periprocedual management of patients receiving therapeutic anticoagula-
tion represents a challenge for dental practitioners, as the risk of bleeding must be 
counterbalanced against the risk of systemic or local thromboembolic phenomena. 
Recommendations for dental interventions in individuals receiving anticoagulation 
therapy remain quite unclear, in spite of practice guidelines from both dental [4] 
and medical [5] fields.
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This chapter aims to discuss the effective ways of managing bleeding com-
plications in dental surgery, mainly in high-risk patients. The role of biosurgical 
materials to prevent or solve these complications, during and after dental surgery 
procedures, will also be addressed, as well as their modes of action, practical appli-
cations, adverse effects, and effectiveness.
2. Normal hemostasis
The physiological mechanism that prevents and hinders bleeding at the area of 
an injury while preserving regular blood flow everywhere else in the circulation is 
called hemostasis [6]. The hemostasis process has two major components. Primary 
hemostasis initiates promptly after vascular injury, and it can be divided into four 
consecutive and superposed stages: (A) vasoconstriction, (B) platelet adhesion, (C) 
platelet activation, and (D) platelet aggregation [7–10]. Primary hemostasis results 
in the formation of a platelet plug [10]. Secondary hemostasis comprises a sequence 
of serine protease zymogens and their cofactors, which interact successively on 
phospholipid surfaces (damaged endothelial cells or platelets), leading to the develop-
ment of covalently cross-linked fibrin [10–12]. This cross-linked fibrin mesh is then 
incorporated into and around the platelet plug. It strengthens and stabilizes the blood 
clot. These two processes are intertwined and occur at the same time [6]. These sys-
tems are regulated by multiple anticoagulant mechanisms, which are responsible for 
maintaining blood fluidity in the absence of injury, generating a clot that is consistent 
with the trauma. Hemostasis and the avoidance of bleeding or thrombosis are directly 
related to the adequate balance between procoagulant and anticoagulant systems [6].
3.  Bleeding diathesis in dental surgery: acquired, autoimmune, or 
genetic
Hemorrhage in dental surgery can be categorized as:
1. Primary hemorrhage: bleeding occurs during surgery
2. Reactionary hemorrhage: bleeding occurs 2–3 hours after surgery
3. Secondary hemorrhage: bleeding occurs until 14 days after surgery, probably 
due to an infection
Hemorrhage can also be categorized according to the area injured: vascular, 
bone, and soft tissue [13, 14]. Bleeding diathesis is an unusual susceptibility to 
bleeding and may be genetic, autoimmune, or acquired (Table 1) [15, 17]. Selected 
bleeding disorders will be covered in this chapter.
3.1 von Willebrand disease and hemophilia
The most prevalent hereditary bleeding disorders are von Willebrand disease 
and hemophilia, affecting 1% of the population and 20,000 people in the USA, 
respectively [18–22]. Dental patients presenting inherited bleeding present a signifi-
cantly higher risk of perioperative bleeding. The frequency and severity of bleeding 
are related to disease-related factors, such as the severity of the hemophilia. Factors 
related to the patient include the level of periodontal disease, vasculopathy or 
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platelet dysfunction, and procedure-related factors (teeth extracted—type and the 
number—or the size of the wound area) [23].
3.2 Immune thrombocytopenia
One example of autoimmune bleeding diathesis is the immune thrombocytope-
nic purpura (ITP), an idiopathic thrombocytopenic purpura condition, character-
ized by isolated thrombocytopenia without a clinically apparent cause [24].
Table 1. 
Hemorrhagic diatheses–adapted from Vezeau [15] and Goswami et al. [16].
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3.3 Common hemostasis-altering medications
The most common acquired bleeding diathesis is the one related to hemostasis-
altering medications. Anticoagulant agents are among the most prescribed medica-
tions in the USA [25]. For decades, anticoagulants have been prescribed to prevent 
arterial and venous thromboembolism [1]. Prolonged bleeding and bruising are some 
of the adverse events related with these medications [4]. The most frequently used 
drugs are therapeutic platelet inhibitors, vitamin K antagonists, or direct oral antico-
agulants. Patients susceptible to hemorrhage may present severe bleeding resulting 
from dental surgery procedures. The use of biosurgical hemostatic agents to decrease 
or control bleeding may be beneficial for patients at risk for bleeding diathesis.
4. Biosurgical topical hemostatic agents in dental surgery
Bleeding complications can occur either in healthy or systemically compromised 
patients. Some patients tend to bleed excessively during or after dental surgery, due 
to different factors, such as anticoagulant therapy, inherited bleeding disorders, 
uncontrolled hypertension, extreme trauma to soft tissues, and non-compliance to 
postoperative recommendations. In these cases, the use of an effective hemostatic 
agent enhances hemostasis, providing a wide spectrum of benefits, such as supe-
rior management of the anticoagulated patient, shorter operation time, as well as 
smaller wound exposure and shorter recovery time.
The ideal topical hemostatic agent should be biocompatible, affordable, and effec-
tive [14, 26, 27]. In recent years, the number of different topical hemostatic agents 
has increased significantly (Table 2). Knowledge and familiarity with the wide range 
of topical hemostatic agents available are essential for dental practitioners, including 
their effectiveness, mode of action, and adverse effects. A well-informed professional 
will be able to opt for the most effective and practical agent for each situation. In 
Table 2. 
Types and trade name of some biosurgical agents–adapted from Pereira et al. [28].
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relation to the use of local hemostatic in dental procedures, available scientific data 
is not homogenous. Most publications use one or more local hemostatic agents to 
compensate for the anticoagulant effect and prevent postoperative bleeding [29]. The 
most common local biosurgical hemostatic agents used in dentistry and approved by 
the Food and Drug Administration (FDA) are listed in Table 2.
Local biosurgical hemostatic agents can be classified into (A) passive or mechan-
ical, (B) active, and (C) flowables [30].
4.1 Passive or mechanical agents
Considered as the most effective agents for small amounts of bleeding, passive 
or mechanical agents provide platelet activation and aggregation. This results in a 
matrix formation in the bleeding area that works as a barrier to stop bleeding, by 
activating the extrinsic clotting pathway and providing a surface that will allow 
coagulation to occur faster [30]. As these agents are biologically inactive, they rely 
on the individual’s own fibrin production to attain hemostasis. Passive hemostats 
are only indicated for individuals with an unscathed coagulation cascade [27]. They 
are generally applied as frontline agents, since they are readily available, do not 
require special storage or handling, and are relatively affordable [14, 27, 31].
4.1.1 Gelatin (Gelfoam®, Surgifoam®, Gelfilm®, Gelita-Spon®, Geli Putty®)
Gelatin is a hydrocolloid derived from acid partial hydrolysis of purified animal 
collagen. It is presented as a gelatin sponge, powder (mixed to form a paste), or film. 
Gelatin can be placed dry or after moistening it with saline [14, 28, 32, 33]. Gelatin-
based products adapt effortlessly to wounds making it appropriate for applica-
tion into irregular surfaces [27]. Although their mode of action is not completely 
understood, gelatin-based products likely act more physically than chemically in the 
coagulation cascade [28, 34]. Affordability, ease of use and good hemostatic activity 
make topical hemostats with gelatin matrix a popular tool for reducing the morbid-
ity caused by hemorrhage [27, 28] after dental extractions and periodontal surgeries.
The most popular absorbable gelatin sponge in dentistry is Gelfoam®. It is 
a hemostatic compressed sponge obtained from purified porcine skin gelatin. 
Gelfoam® is capable of absorbing many times its weight of whole blood [35]. 
Generally, when applied in soft tissues, its complete absorption occurs within 
4–6 weeks.
4.1.2 Collagen (Helistat®, Instat®, Helitene®)
Collagen absorbable products are nontoxic and non-pyrogenic. They are sourced 
from either bovine dermal collagen or bovine tendon. Collagen hemostats provide 
a matrix for clot formation and consolidation. These products also improve clotting 
factor release and platelet aggregation and degranulation, thereby breaking up clot 
formation. Their presentation in sheets and flours allows for easy adaptation and 
adhesion to irregular surfaces. Although they are commercialized at a higher price 
than gelatin-based hemostats, hemostasis can usually be accomplished relatively 
quicker (1–5 min). Collagen absorbable products are easily removed, reducing the 
risks of rebleeding and the need for various applications. They are absorbed in 
8–10 weeks if remained in place. Adverse effects linked to bovine collagen products 
might include swelling and allergic reaction [30].
Helistat® is a collagen-based product originated from purified and freeze-dried 
bovine flexor tendon and is available as a spongelike structure [14, 27]. Helistat® 
can hold many times its own weight of fluid, as it is highly absorbent. Collagen 
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induces platelet agglomeration when in contact with blood. In order to achieve 
hemostasis, Helistat® must be kept at the site (approximately 2–5 minutes). 
Subsequently, it can be removed, replaced, or left in place. It is easily manipulated, 
and it must be handled dry, and any excess must be removed. Complete reabsorp-
tion occurs within 14–56 days [14, 27, 36]. Helistat® may foster bacterial growth, 
acting as a nidus for abscess formation [14, 27, 37]; therefore, it should not be placed 
in wounds with any kind of contamination or infection. Possible adverse reactions 
of Helistat® or similar products are allergic reaction, foreign body reaction, and 
adhesion formation [27, 38].
4.1.3 Cellulose-based products
4.1.3.1  Oxidized regenerated cellulose (Surgicel®, Oxycel®, Surgicel Nu-Knit®, 
Surgicel Original®, Surgicel Fibrillar®, Interceed®, Gelita-Cel®)
Simple oxidized cellulose was first introduced in the early 1940s in the USA. In 
the 1960s, a new topical hemostatic-oxidized regenerated cellulose (ORC) was 
launched as a meshwork made from treated and sterilized cellulose—Surgicel®. 
ORC products are originated from vegetal-based alpha cellulose, available in 
absorbable knitted fabrics (low or high density), and prepared as sterile fabric 
meshworks. They are ready-to-use products that may be kept at room temperature 
and absorb 7–10 times its own weight [27, 30]. ORC cause contact activation and 
platelet activation, and, when absorbed, a gelatinous mass is created, assisting in 
the establishment of the clot formation [30]. Thrombin is ineffective with these 
agents due to low-pH factors. ORC are utilized in the management of capillary, 
venous, and small arterial bleeding, and they require dry application, without 
addition of saline or thrombin [27, 39] and are absorbed within 4–8 weeks, depend-
ing on the volume applied, the tissue bed, and the magnitude of blood saturation 
[27, 40–42]. To prevent delayed healing, excessive volumes should be removed [27]. 
ORC should not be used in osseous defects as it may intervene with bone regenera-
tion [14, 27, 31]. Adverse effects also include reactions related to the acidic nature of 
ORC. This characteristic may induce necrosis and inflammation of the surrounding 
tissue and makes thrombin inefficient with these agents. When left in the wound, 
they may lead to fluid encapsulation and foreign body reaction [14, 27].
The most common commercial products in this category are Surgicel®, 
Oxycel®, and Surgicel Nu-Knit®. Surgicel® and Surgicel Nu-Knit® come in knit, 
solid fiber form, whereas Oxycel® comes in knit, hollow fiber form; however, they 
function basically in a similar manner [30].
4.1.3.2 Oxidized cellulose (ActCel®, Gelita-Cel®)
Oxidized cellulose (OC) agents are produced from sterilized and treated cel-
lulose, presented as a meshwork. In the presence of blood, they present a three- to 
fourfold increase in volume and are converted into gel. OC dissolve completely 
in 1–2 weeks into biodegradable end products glucose and water, and they do not 
interfere with wound healing [14, 27].
ActCel® binds to calcium ions, resulting in more calcium available for the coagu-
lation cascade [14, 27, 37]. Biochemically, it intensifies the coagulation process by 
increasing platelet aggregation and physically by 3D clot stabilization. ActCel® is espe-
cially indicated in third molar extractions, to avoid the occurrence of dry sockets, and 
in orthognathic and periodontal surgeries [27]. ActCel® is hypoallergenic, as it does 
not contain collagen, thrombin, or chemical additives. It also has important bacterio-
static properties [27, 43], which are particularity relevant in infected wounds [27].
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Gelita-Cel® is a relatively quick acting, oxidized resorbable cellulose hemostatic 
gauze of natural origin. It presents a decreased risk for encapsulation, as it resorbs 
as fast as 96 hours [14, 27, 37].
4.1.4 Polysaccharide hemospheres (Arista™AH)
Polysaccharide hemospheres are a fairly new class of topical biosurgical hemo-
static agents, produced from vegetable starch, and they contain no animal or human 
elements. They are commercially presented in powder form. Polysaccharide hemo-
spheres increase barrier formation by creating a hydrophilic effect, dehydrating the 
blood, and concentrating its solid components [14, 27]. Due to their 3D scaffold, 
they are devised to enhance clot formation and organization, even in the absence of 
intrinsic coagulation activity [14, 44, 45]. Polysaccharide hemospheres should be 
used with caution in diabetic patients, as they consist of sugars [27].
Arista™AH is the only FDA-approved product in the polysaccharide hemosphere 
category. It is used in dental surgery as an adjunctive hemostatic agent, when 
conventional mechanical procedures, such as pressure and ligature, are not effective 
or practical.
4.1.5 Adhesives (BioGlue®)
Hemostatic adhesives are often used as adjuncts to standard hemostatic pro-
cedures to control bleeding from surgical areas [30]. One of the most well-known 
products in this category is BioGlue®. It consists of a solution of 10% glutaralde-
hyde and 45% bovine albumin solution purified by precipitation, heat, and chro-
matography radiation [28, 46]. BioGlue® has been extensively used for its sealants 
and hemostatic characteristics. The risk of leaking through the suture tracks is the 
main disadvantage of BiolGue® [27]. In the search for newly created adhesives with 
the chemical features and the safe reabsorptive profile required to benefit dental 
surgery patients, several clinical trials are currently in process.
4.2 Active agents
Active hemostatic agents are biologically active, as they play a direct role in the 
coagulation cascade, inducing the formation of a fibrin clot [26, 27].
4.2.1 Topical thrombin (Thrombin-JMI®, Evithrom®, Recothrom®)
Thrombin is key to hemostasis, as well as to the inflammatory and cell signal-
ing processes. It is the base of the fibrin clot, fostering the transformation of 
fibrinogen to fibrin [28]. Topical thrombin hemostats are originated from either 
bovine or human plasma, and they can also be produced through recombinant 
DNA techniques [14, 27]. In the past, the only thrombin hemostat available was 
composed of bovine plasma (Thrombin-JMI). Although it has proven to be efficient 
in terminating bleeding, bovine thrombin induces an important immune response 
[28, 47]. Individuals on hemodialysis, with increased levels of antibodies against 
topical bovine thrombin, had higher incidence of vascular access thrombosis, 
severe coagulopathy, and bleeding after exposure to bovine thrombin [28, 48]. As 
an attempt to avoid these hazardous effects, thrombin derived from human plasma 
(Evithrom®) and recombinant human thrombin (Recothrom®) were developed. 
In 2010, Browman et al. [49] demonstrated, in a comparative study between recom-
binant human thrombin and bovine thrombin, that human recombinant thrombin 
showed the same efficacy in surgical hemostasis, a comparable safety profile, and 
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a remarkably lower immune response than bovine thrombin. Thrombin may be 
applied topically, as a solution combined with gelatin sponges mixed with a gelatin 
matrix, as a dry powder, or as a spray [14, 27]. It is commonly used in conjunction 
with Gelfoam® to stop moderate to severe bleeding.
4.2.2 Fibrin sealants (Tisseel®, Evicel®, Crosseal™)
Fibrin sealant or fibrin glue originates from bovine and/or human blood 
components and simulates the last phases of the coagulation cascade, generating 
a fibrin clot [30]. These agents control local, as well as diffuse, bleeding from the 
surgical area. Nevertheless, they are ineffective in controlling intense bleeding. 
Its use in dentistry includes tooth extraction sites, bone grafting, and periodontal 
surgery [14].
Tisseel® was the first fibrin sealant approved by the FDA. It has in its com-
position human thrombin and fibrinogen, intermixed with aprotinin and CaCl2. 
Because aprotinin is a bovine protein, it is a potential allergen. Multiple exposures 
may cause allergic reactions, as well as anaphylactic reaction approaching lethality 
[30, 50]. As for its ideal application, a dry operating field is required; Tisseel® is 
particularly effective when applied prior to bleeding. In this situation, fibrinogen 
may polymerize before blood pressure increases local microcirculation flow. When 
used after the onset of bleeding, one should apply local pressure over the wound to 
allow polymerization [28, 51]. Tisseel® is available in a pre-filled syringe, allowing 
for effective application using the EasySpray and DuploSpray MIS systems.
Another option for fibrin sealants, Evicel®, originates from pooled human 
plasma. It is available as two separate vials of fibrinogen and human thrombin. 
Prior to use, the two deep frozen solutions must be thawed and mixed after defrost-
ing and heating up (20–30°C) [30].
Crosseal™ is a virally inactivated, second-generation surgical sealant. It is 
produced from concentrated human clottable proteins, namely, biological active 
component (BAC), which contains the active component fibrinogen, and human 
α-thrombin (1000 IU/ml) [52]. This fibrin sealant is applied using an application 
device which drips/sprays Crosseal™ onto the bleeding site.
4.3 Flowables (Surgiflo®, Floseal®)
There are two main categories of flowable biosurgicals: products containing 
porcine gelatin, which can be combined with thrombins (bovine, human-pooled 
plasma thrombin, or rhThrombin), and bovine collagen-based agents, packed with 
human-pooled plasma thrombin. The flowable agents are deemed the most effective 
of all the local hemostatic agents [30, 53].
Surgiflo® is an absorbable, sterile, hemostatic porcine gelatin matrix, combined 
with Thrombin-JMI, a topical bovine-derived thrombin. It should be placed directly 
to the bleeding areas to activate the hemostatic process [30]. A compression period 
is required for polymerization of the sealant components [28].
Floseal® consists of a bovine gelatin matrix, plasma-extracted human throm-
bin, and CaCl2. Its gelatin granules expand (10–20%), as it comes in contact with 
blood, producing a seal when the product is applied to a bleeding area [27, 30]. 
The thrombin fraction of the product triggers the regular pathway of the coagula-
tion cascade, converting fibrinogen to a fibrin polymer and creating a clot around 
the firm matrix [27], which is reabsorbed within the expected period of standard 
wound healing (6–8 weeks) [14, 27, 33, 42, 54]. A distinctive feature of Floseal® is 
the need for the presence of blood for activation [30, 55]. Neither compression, nor 
a dry surgical field is required for its application [28].
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Because of this biosurgical flowability, they can easily adapt to irregular wounds. 
Flowables have been utilized as frontline topical hemostats in major dental surger-
ies, in patients where conventional procedures are ineffective. They can be utilized 
as an adjunct to hemostasis in practically all dental surgical interventions. Flowables 
are effective on both hard and soft tissues [27, 30]. They have a risk of transmitting 
infectious agents and are contraindicated in patients who are allergic to materials of 
bovine origin [27].
5. Effectiveness of different biosurgical hemostatic agents in dentistry
Although traditional methods, such as ligature and manual pressure, can 
promote hemostasis, they are not an effective approach of bleeding control in less 
accessible sites and complex injuries. Furthermore, bleeding control is especially 
challenging in patients presenting acquired or congenital coagulation disorders.
Topical biosurgical hemostatic agents comprise a wide range of products aiming at 
minimizing the risk of bleeding. In recent years, several clinical trials have analyzed 
the effectiveness, advantages, and limitations of biosurgicals, as well as performed 
comparisons among the different types of biosurgicals and other non-biologic agents. 
Despite the beneficial effect of these local hemostatic agents in preventing bleeding 
in dental surgery, available data comparing their effectiveness and efficiency is still 
scarce and inconclusive. Methodological heterogeneities, such as the lack of a stan-
dard therapy and comparable treatment regimens, are noticeable among studies, as 
well as the reduced number of randomized controlled trials [2, 56–70].
In summary, local hemostatic agents are very distinct products with diverse indi-
cations. Presently, there is no definite evidence-based approach to guide the dental 
practitioner when selecting a local hemostatic agent. They must be aware of the 
characteristics of each single hemostatic agent, to elect the most suitable product 
for every particular clinical situation. In addition, current available data shows that 
no topical agent can be regarded as superior or more effective than the others [2]. 
Further experimental research and controlled clinical trials are warranted to define 
the most cost-effective biosurgical hemostatic agents in dentistry.
6. Preoperative assessment and risk of bleeding
The dental practitioner should assess the bleeding risk of the patient, as well as 
the bleeding risk of the surgical intervention, preoperatively. After assessing both 
bleeding risks, the professional can then conceive an intraoperative and postopera-
tive plan. The international normalized ratio (INR) must be evaluated in patients 
reporting an elevated risk of bleeding. While a standard parameter of coagulation 
has an INR of 1 [71], the therapeutic range runs from 2.0 to 3.5. In this case, it is 
recommended to use local hemostatic measures independently or in combination 
with conventional methods. These agents can be used before, during, and after 
dental surgeries.
6.1 Preoperative assessment
• Comprehensive medical history, including all medications in the patient’s regi-
men, to identify potential bleeding issues prior to the surgery [26].
• In order to decrease surgical bleeding, patients receiving anticoagulant therapy 
may need to break up exodontia into multiple appointments [26, 72].
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• Laboratory values such as platelet count, INR, and prothrombin time are of 
critical value in medically compromised patients [26].
• Demographic risk factors (female sex and older age) [73].
• Supplemental patient-related risk determinants: diabetes mellitus, hyperten-
sion, obesity, hemostatic disorders, renal impairment, and other major organ 
system failures [73–75].
• Timing of the appointment: early morning visits allowing patients to return to 
the dental office in case of postsurgical hemorrhage [26].
6.2 Identifying patients at risk of bleeding
Patients at a higher bleeding risk are those reporting family history of bleeding 
and previous bleeding problems after dental surgery or trauma and individuals 
using medications, such as aspirin, anticoagulants, and/or long-term antibiotics. 
Any illnesses associated with bleeding problems, such as leukemia, congenital 
heart disease, liver disease, or hemophilia, present a higher risk of bleeding. The 
dental professional needs to be aware and prepared for any intercurrence, during 
or after a surgical procedure. Individuals presenting advanced periodontal disease 
are also considered as having a higher risk of perioperative bleeding. In such cases, 
the surgical plan should include a preoperative phase, consisting of scaling and 
root planning and a proper chlorhexidine gluconate mouth rinse regimen, 2 weeks 
before an elective procedure [26].
The risk of bleeding of a dental intervention may be ranked as high, moderate, 
and low [25, 76–78]. In most patients, antithrombotic therapy is not interrupted 
before dental interventions with low bleeding risk, due to the disastrous complica-
tions of thrombosis (Table 3) [25, 76–78]. Moderate and high bleeding potential 
interventions might need the temporary discontinuation of the antithrombotic 
therapy [25, 76–78].
Table 3. 
Dental interventions that do not require anticoagulation therapy interruption*–adapted from Kaplovitch and 
Dounaevskaia [25].
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7. Bleeding in dental surgery: clinical implications
Dental surgical interventions are considered by most recommendations, 
as minor procedures presenting self-limited blood loss and low bleeding risk. 
Bleeding, in most cases, can be managed with local hemostatic agents [79, 80].
7.1  Should anticoagulants, antiplatelets, or direct oral anticoagulants be 
discontinued for minor dental surgeries?
The dental care of individuals receiving therapeutic anticoagulation becomes 
critical when invasive procedures are needed. At this time, the clinician must decide 
either to maintain the anticoagulation therapy and risk bleeding complications or 
withdraw the anticoagulation medication and risk developing systemic thrombosis 
[1]. After decades of controversial data, there is currently a nearly unanimous 
consensus that anticoagulation therapy, for most dental surgeries, should not be 
discontinued. The higher risk of bleeding complications is compensated by the 
elevated risk of developing thromboembolic complications [1, 81–84].
National dental and medical group statements and multiple evidence-based 
clinical guidelines have considered the issue independently and support the 
maintenance, for most dental patients, of anticoagulation therapy (American 
Dental Association; American Academy of Dental Sleep Medicine; American Heart 
Association; American College of Cardiology; American Academy of Neurology; 
American Society of Anesthesiologists; Society for Neuroscience in Anesthesiology 
and Critical Care; American College of Chest Physicians (ACCP)) [1]. In a 2012 
statement [76], the ACCP recommended continuing anticoagulation therapy with 
warfarin, with the additional utilization of a local hemostatic. The ACCP advised 
a 2–3-day anticoagulation therapy suspension, in order to lower the INR levels to a 
range of 1.6 and 1.9 [76, 85].
Lately, the dental care of patients receiving anticoagulant treatment has been 
the focus of expressive scientific interest, in both dental and medical fields. A 
recent literature review showed that only 31 (0.6%) of more than 5400 patients 
receiving over 11,300 dental surgical interventions while continuing to take vitamin 
K antagonist anticoagulants (warfarin in most cases) demanded more than local 
maneuvers for hemostasis. No cases of fatal hemorrhage were reported. In over 
2600 individuals whose anticoagulation was discontinued for dental interventions, 
22 thromboembolic complications (0.8% of medication withheld), including 6 fatal 
events (0.2% of medication withheld), were observed [83]. Similar results have 
been shown in a literature review of dental surgery and antiplatelet medications. 
Of more than 1200 patients receiving over 2300 dental surgical procedures while 
continuing their antiplatelet medications (aspirin in most cases), only 2 (0.2%) 
needed more than local measures for hemostasis. Conversely, in over 320 individu-
als undergoing 370 antiplatelet interruptions for dental procedures, 17 (5.3%) 
suffered thromboembolic complications [86].
Available data shows that the majority of dental interventions can be safely 
conducted in patients receiving anticoagulation treatment, when considering older 
medications [4]. However, there are fewer studies reporting the provision of dental 
care in individuals using newer direct oral anticoagulants. The clinical implications 
of these newer anticoagulant and antiplatelet therapies have only been recently 
investigated [80, 87]. The protocol followed by the dental practitioner when manag-
ing these patients varies significantly and shows inconsistencies reflecting the lack 
of large-scale studies and evidence-based clinical guidelines [80, 88, 89]. The risk 
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of postoperative bleeding after invasive periodontal treatment in individuals using 
different anticoagulation therapies was assessed, retrospectively, in 456 individuals 
receiving an antiplatelet and/or anticoagulant therapy [90]. Data was collected after 
484 invasive periodontal interventions, with 99.6% of patients continuing their medi-
cations during the procedures. Postoperative bleeding was reported only following 
three interventions (0.35%), and it was controlled with local hemostatic maneuvers. 
Although the authors did not specify which type of local hemostatic procedure was 
used, this retrospective study showed a very low risk of bleeding in patients receiv-
ing an invasive periodontal intervention while using an anticoagulant or antiplatelet 
medication [90]. These results support the recommendation that such medications do 
not need to be discontinued in anticipation to invasive periodontal interventions.
Extended inter- or postoperative bleeding following dental surgery is infrequent, 
seldom demanding anything more than the use of local hemostatic biosurgicals. The 
judgment of whether or not to interrupt anticoagulation treatment can be both intri-
cate and dynamic, and it should be based on the indication for pharmacological ther-
apy, as well as previous thromboembolic history. The discontinuation of anticoagulant 
therapy may be required in dental interventions with moderate and high bleeding risk 
[25, 76–78]. Currently, most clinicians dealing with anticoagulant management tend 
to personalize the periprocedural management of the bleeding potential, according to 
the individual risk of each procedure—low, moderate, or high—following the current 
clinical practice recommendations based on best evidence and maintaining the anti-
coagulant therapy. Thereby, the patient anticoagulant regimen should be continued in 
specific low-risk dental procedures, without consultation or fear of disproportionate 
bleeding demanding additional intervention (Table 3) [25].
7.2 Common anticoagulants and potential interactions with dental medications
Undoubtedly, anticoagulant agents are effective in preventing thromboembo-
lism. Nevertheless, their potential for critical adverse effects cannot be ignored. The 
use of antithrombotic medications is the most frequent cause of an adverse drug 
event requiring individuals to seek out emergency care [25, 91]. The majority of 
drug interactions with anticoagulants lead to elevated risk of bleeding. The nature 
of the interactions cannot be predicted, as they are expressed through both pharma-
codynamic mechanisms and pharmacokinetic properties [25].
Regarding patient safety, potential risk for interaction, as well as knowledge 
of appropriate prescribing and monitoring, is crucial. Equally decisive is select-
ing the appropriate anticoagulant agent and monitoring the potential for drug–
drug interaction [10–15, 17, 25]. Common anticoagulants and their interaction 
with the most common medications prescribed for dental patients are described 
in Table 4 [25, 92–98].
7.3  What is the difference in the risk of bleeding between patients ongoing 
anticoagulant therapy and patients not treated?
Most studies evaluating the occurrence of peri- and postoperative bleeding show 
anticoagulation therapy can be maintained when adequate local hemostatic maneu-
vers are used.
As an example, a controlled clinical trial compared the occurrence of bleed-
ing following dental extractions in individuals receiving oral anticoagulants 
(experimental group) versus patients that had never received oral anticoagulant 
therapy (control group). Tooth extractions were performed, and a piece of oxidized 
cellulose was placed only into the sockets in the experimental group. The wound 
borders were sutured, and a gauze saturated with tranexamic for 30–60 minutes 
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was applied with pressure in the wound. Both groups presented similar bleeding 
complications [99]. In a similar clinical trial [100], 161 tooth extractions were 
performed in patients undertaking warfarin. After tooth extraction, an oxidized 
cellulose gauze was placed in the socket, and the wound was sutured. Patients were 
assigned to four groups, according to their INR range (INR was 1.5–1.99 in group 1; 
2.0–2.49 in group 2; 2.5–2.99 in group 3; and 3.0–3.7 in group 4). No significant 
differences were found in the postoperative bleeding among groups.
8. Conclusions
Based on the latest evidence and clinical practice recommendations on the periop-
erative management of dental patients receiving direct oral anticoagulants, on single or 
dual antiplatelet therapy or vitamin K antagonists, as well as on the current scientific 
knowledge on biosurgical hemostatic agents, the following conclusions can be made:
• The majority of dental procedures can be securely executed without the with-
holding of anticoagulants, using only local hemostatic therapy. In fact, current 
recommendations and consensus support the continuation of antiplatelet 
or anticoagulant therapy. Discontinuing these drugs can increase the risk of 
thromboembolism, at the cost of minor bleeding, which can be restrained with-
out difficulty. The appropriate use of local hemostatic measures, such as topical 
biosurgical hemostatic agents, should always be considered whenever indicated.
Table 4. 
Common anticoagulants and potential interactions with dental medications–adapted from Kaplovitch and 
Dounaevskaia [25].
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• In order to safely treat a patient receiving anticoagulant therapy, familiarity with 
anticoagulants and with the potential for drug–drug interactions is required, in 
addition to knowledge about the topical hemostatic options available.
• Topical biosurgical hemostatic agents are diverse agents with distinct indica-
tions. The dental practitioner must be aware of the properties of each single 
agent, in order to properly select the product needed in each different clinical 
condition.
• Based on current available data, no topical hemostatic agent can be regarded 
as superior or more effective than the others. Further experimental research 
and controlled clinical trials are warranted to define the most cost-effective 
biosurgical hemostatic agents in dentistry.
• A definite protocol for excessive bleeding is still required for dental surgery in 
patients with hemorrhagic diathesis. The most effective local hemostatic agent 
with lesser complications should be determined in future research, considering 
their availability and cost-effectiveness.
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